Literatura académica sobre el tema "Acute Leukaemia - Treatment"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Acute Leukaemia - Treatment".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Acute Leukaemia - Treatment"
Kuzmits, Rudolf, Paul Aiginger, Matthias M. Müller, Günter Steurer y Werner Linkesch. "Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells". Clinical Science 71, n.º 1 (1 de julio de 1986): 81–88. http://dx.doi.org/10.1042/cs0710081.
Texto completoIvanovic, Mirjana, Olivera Jovicic, Jelena Mandic, Dusko Bogetic y Marcello Maddalone. "Oral manifestations of acute leukaemia". Srpski arhiv za celokupno lekarstvo 139, n.º 1-2 (2011): 103–6. http://dx.doi.org/10.2298/sarh1102103i.
Texto completoSkarsgård, Lisa Stenman, Mattias K. Andersson, Marta Persson, Ann-Cathrine Larsen, Sarah E. Coupland, Göran Stenman y Steffen Heegaard. "Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations". BMJ Open Ophthalmology 4, n.º 1 (octubre de 2019): e000362. http://dx.doi.org/10.1136/bmjophth-2019-000362.
Texto completoArruda, Walter Oleschko, María Belén Montú, Marcelo de Souza R. de Oliveira y Ricardo Ramina. "Acute myeloid leukaemia induced by mitoxantrone: case report". Arquivos de Neuro-Psiquiatria 63, n.º 2a (junio de 2005): 327–29. http://dx.doi.org/10.1590/s0004-282x2005000200024.
Texto completoBhalla, Amit. "Clofarabine: a next-generation deoxyadenosine analogue". International Journal of Basic & Clinical Pharmacology 7, n.º 5 (23 de abril de 2018): 1048. http://dx.doi.org/10.18203/2319-2003.ijbcp20181660.
Texto completoBurnett, Alan K. "Treatment of acute myeloid leukaemia". Clinical Medicine 13, Suppl 6 (diciembre de 2013): s58—s61. http://dx.doi.org/10.7861/clinmedicine.13-6-s58.
Texto completoApostolidou, Effrosyni, Ronan Swords, Yesid Alvarado y Francis J. Giles. "Treatment of Acute Lymphoblastic Leukaemia". Drugs 67, n.º 15 (2007): 2153–71. http://dx.doi.org/10.2165/00003495-200767150-00004.
Texto completoLÖWENBERG, B. "Treatment of acute myelogenous leukaemia". Journal of Internal Medicine 242 (julio de 1997): 17–22. http://dx.doi.org/10.1111/joim.1997.242.s740.17.
Texto completoOmura, GeorgeA. ""MAINTENANCE TREATMENT" FOR ACUTE LEUKAEMIA". Lancet 328, n.º 8516 (noviembre de 1986): 1154. http://dx.doi.org/10.1016/s0140-6736(86)90553-2.
Texto completoBurnett, AK y OB Eden. "The treatment of acute leukaemia". Lancet 349, n.º 9047 (enero de 1997): 270–75. http://dx.doi.org/10.1016/s0140-6736(96)08086-5.
Texto completoTesis sobre el tema "Acute Leukaemia - Treatment"
Thornton, Nadia. "L-alanosine : selective treatment in relapsed childhood acute lymphoblastic leukaemia". Thesis, University of Newcastle Upon Tyne, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.440588.
Texto completoJohnson, Peter R. E. "The biology and treatment of acute myeloid leukaemia in elderly patients". Thesis, University of Aberdeen, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306856.
Texto completoLehtinen, S. (Satu). "Neurotoxicity in children after treatment for acute lymphoblastic leukaemia and methotrexate neurotoxicity in a controlled animal model". Doctoral thesis, University of Oulu, 2003. http://urn.fi/urn:isbn:9514270339.
Texto completoHallböök, Helene. "Acute lymphoblastic leukaemia in adult patients : studies of prognostic factors, treatment results and in vitro cellular drug resistance /". Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.
Texto completoHallböök, Helene. "Acute Lymphoblastic Leukaemia in Adult Patients : Studies of Prognostic Factors, Treatment Results and in vitro Cellular Drug Resistance". Doctoral thesis, Uppsala University, Department of Medical Sciences, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5768.
Texto completoTreatment results and clinical characteristics in adult acute lymphoblastic leukaemia (ALL) were evaluated regarding three issues: a new treatment with cytarabine up-front, stem cell transplantation and a comparison between adult and paediatric treatment protocols. All studies were conducted on a national basis. Furthermore, activity of imatinib was investigated by in vitro cytotoxicity assay.
The national protocol was evaluated in 153 adult ALL patients. A high complete remission rate, 86%, was achieved with 29% overall survival at 3-years. Favourable outcome was identified in patients < 40 years with precursor B phenotype and continuous complete remission was higher for precursor B compared to T-ALL.
Stem cell transplantation was evaluated in 187 patients. No differences in outcome between allogeneic and autologous transplantation were found, with the exception of Philadelphia-positive ALL, in which allogeneic transplantation was preferable. Limited chronic graft-versus-host disease (compared to none) resulted in superior disease free survival.
The paediatric NOPHO-92 and the Adult protocols were evaluated for 243 ALL-patients. Superior remission rate and survival were achieved for 10-18 year-olds treated according to the Paediatric protocol compared to both 15-25 and 25-40 year-olds treated according to the Adult protocol. Treatment protocol was a significant prognostic factor for patients aged 15-20 years.
Fluorometric Microculture Cytotoxicity Assey was used to analyze 15 tumour cell samples from ALL patients. High concordance was determined between in vitro sensitivity to imatinib and presence of BCR-ABL. Daunorubicin, prednisolone and cytarabine had the greatest benefit from a combination with imatinib.
The national adult treatment protocol’s results were consistent with international trials regarding precursor B ALL but may be under performing for T-ALL. Adolescents may benefit from treatment according to the Paediatric protocol. No difference in outcome between allogeneic and autologous stem cell transplantation was determined except for Philadelphia-positive patients, despite the indication of a graft-versus-leukaemia effect.
Krishnan, Shekhar. "In vitro evaluation of asparagine endopeptidase as a candidate biomarker of treatment failure in childhood acute lymphoblastic leukaemia". Thesis, Queen Mary, University of London, 2011. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1294.
Texto completoLiem, Natalia Women's & Children's Health Faculty of Medicine UNSW. "The development of an in vivo model to study the biology and treatment of childhood acute lymphoblastic leukaemia (ALL)". Awarded by:University of New South Wales. Women's & Children's Health, 2007. http://handle.unsw.edu.au/1959.4/40537.
Texto completoFordham, Sarah Elizabeth. "DNA mismatch repair and cellular response to cytarabine : implications for the pathogenesis and treatment of therapy-related acute myeloid leukaemia". Thesis, University of Newcastle Upon Tyne, 2011. http://hdl.handle.net/10443/1366.
Texto completoBurrett, Julie Ann. "Identification of randomized trials for inclusion in meta-analyses of treatments for childhood acute lymphoblastic leukaemia, and investigation of factors leading to publication bias". Thesis, Open University, 2003. http://oro.open.ac.uk/22376/.
Texto completoData: The set of randomized trials identified by the Childhood Acute Lymphoblastic Leukaemia (ALL) Collaborative Group was used. This consists of 149 trials comprising 243 randomized comparisons (randomizations), starting prior to 1 January 1988, reported in 257 articles, published prior to 1 January 2000. Each mention of a randomization in an article (irrespective of whether results are given) generates a publication record, of which there are 610.
Methods: The main focus is on identifying which trial characteristics lead to a delay in publication of a randomization. Time to the first mention of a randomization in an article (irrespective of whether any results are given) and to the first reporting of its results are both modelled using ordinary linear regression (the independence model). However, when these analyses are extended to include all mentions and all reportings of results respectively, non-independence necessitates the use of techniques for dealing with repeated measures. In such cases the independence model is the starting point, the residuals from which are used to form the covariance matrix, which in turn is used to suggest plausible correlation structures for repeated measures models. Generalised estimating equation (GEE) analysis is used to select an appropriate correlation structure, and a linear mixed effects model serves to confirm this. The conclusions are then discussed in the context of other studies identified. Finally logistic regression is used to identify trial characteristics associated with a randomization remaining unpublished, and Poisson and negative binomial models to identify those affecting frequency of reporting.
Results: Evidence was found of ‘pipeline bias’ in the reporting of first results since, although direction of effect was not found to be significant, highly statistically significant results are published faster than others. However this is not so for first mentions. Negative results (i.e. those in favour of the standard/control) arm were submitted for first publication faster than all others, although this did not effect time to publication. In addition, geographic location is an important predictor of whether a randomization is ever mentioned in an article, frequency of mentions and of time to first publication and results from single-centre trials are published more frequently than those with multi-centre participation.
Conclusions: Although ‘pipeline bias’ was identified in the analysis of time first reporting of results, it was not present in the analysis of time to first mention, and so not a problem for those wishing only to identify randomized trials for inclusion in meta-analyses. The importance of geographic location suggests that the practice of contacting known trialists is worthwhile in addition to the computerised literature searches and should be continued.
"Daunorubicin kinetics and drug resistance in leukaemia". Thesis, University of Technology, Sydney. Faculty of Science, 1996. http://hdl.handle.net/10453/20146.
Texto completoThe aims of this thesis were to examine: (1) plasma and cellular pharmacokinetics of daunorubicin and its major metabolite daunorubicinol in patients with acute leukaemia, and the relationships between pharmacokinetics, patient response and the presence of P glycoprotein; (2) actions of the multidrug resistance reversing agents cyclosporin A and trifluoperazine, at clinically achievable concentrations, on daunorubicin accumulation and retention in human leukaemia cell lines and patients with acute leukaemia; and (3) effect of daunorubicin on the cell membrane of both sensitive and resistant cell lines, with and without the multidrug resistance reversing agents. Twenty-seven patients with acute leukaemia received daunorubicin as part of induction therapy. The plasma and cellular levels of daunorubicin and its metabolite daunorubicinol were determined using HPLC. There were no significant differences between patients who went into complete remission (12 out of 23) compared to those who did not respond for any of the plasma pharmacokinetic parameters. There was a significant difference in the cellular daunorubicin and daunorubicinol area under the concentration-time curve between responders and non responders (p less than 0.02), as well as in cellular Cmax, cellular clearance and cellular volume of distribution. Eleven patients were P glycoprotein positive and 10 P glycoprotein negative (no sample available for 2 patients). There was no correlation between patient response and the presence of P glycoprotein; nor a correlation between the cellular concentration of daunorubicin or daunorubicinol and P glycoprotein. Patients responding to chemotherapy had higher cellular daunorubicin and daunorubicinol compared to non responders. In contrast to in vitro studies, overexpression of P glycoprotein was not the reason for the lower cellular daunorubicin levels. Cyclosporin A was capable of increasing both cellular accumulation and retention in the drug resistant CEM/VLB and HL 60/ADR cell lines, but not in the drug sensitive CEM and HL 60 cell lines. Trifluoperazine had no effect in any of the four cell lines. In contrast to the cell line findings, only the combination of cyclosporin A and trifluoperazine were able to increase both accumulation and retention in the blast cells of patients at initial presentation. The multidrug resistant reversing agents alone had no effect in increasing accumulation or retention in the blast cells of P glycoprotein positive patients, nor patients in relapse. The cell line studies show that at clinically relevant concentrations only cyclosporin A is capable of increasing daunorubicin accumulation in both the drug resistant P glycoprotein positive (VLB) and P glycoprotein negative (ADR) cell lines. Thus, cyclosporin A does not work only by inhibiting the actions of P glycoprotein. Trifluoperazine was unable to reverse drug resistance at clinically relevant concentrations in either cell lines or patient blast cells. However, the combination of cyclosporin A and trifluoperazine increased accumulation in patient blast cells at initial presentation, suggesting that these agents may be more useful in patients at initial presentation than relapse. Daunorubicin was immobilised by linking it to poly vinyl alcohol and the effect of immobilised-daunorubicin was studied on the four cell lines above. The immobilised-daunorubicin was able to decrease cell growth in the drug sensitive HL 60 cell line but not in the drug resistant VLB or ADR cell lines. Poly vinyl alcohol itself was cytotoxic to the CEM cell line. The multidrug resistance reversing agents cyclosporin A and trifluoperazine were only capable of increasing cytotoxicity in the HL 60 cell line, with no effect in the drug resistant VLB or ADR cell lines.
Libros sobre el tema "Acute Leukaemia - Treatment"
National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2003.
Buscar texto completoNational Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence, 2002.
Buscar texto completoRooney, Maria Anne. An evaluation of the immune competence of children with common Acute Lymphoblastic Leukaemia, both during and post-treatment, by an investigation of the Lymphocyte sub-populations using monoclonal antibodies and the Alkaline Phosphatase Anti-Alkaline Phosphatase technique. [s.1: The Author], 1989.
Buscar texto completoMendez, Irvin. Acute Myeloid Leukaemia: Symptoms, Diagnosis and Treatment. Nova Science Publishers, Incorporated, 2018.
Buscar texto completoM, Carella Angelo, ed. Chronic myeloid leukaemia: Biology and treatment. London: Martin Dunitz, 2001.
Buscar texto completoGoldman, John M., Angelo M. Carella, George Q. Daley, Connie J. Eaves y Hehlmann Rudiger. Chronic Myeloid Leukaemia: Biology and Treatment. Taylor & Francis Group, 2003.
Buscar texto completoMcCann, Shaun R. Leukaemia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0007.
Texto completoCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne y Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.
Texto completoCutter, David y Martin Scott-Brown. Treatment of cancer. Editado por Patrick Davey y David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.
Texto completoMcCann, Shaun R. Molecules, genes, and gene therapy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198717607.003.0009.
Texto completoCapítulos de libros sobre el tema "Acute Leukaemia - Treatment"
Jacobs, P., L. Wood y N. Novitzky. "Treatment of Adult Acute Lymphoblastic Leukaemia". En Acute Leukemias II, 428–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_79.
Texto completoBader, Peter, Franco Locatelli y Christina Peters. "Paediatric Acute Lymphoblastic Leukaemia (ALL)". En The EBMT/EHA CAR-T Cell Handbook, 57–59. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_10.
Texto completoRees, J. K. H., R. Gray y F. G. J. Hayhoe. "The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia". En Acute Leukemias, 35–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_6.
Texto completoOrtega, J. J., G. Javier y T. Olive. "Treatment of Standard- and High-Risk Childhood Acute Lymphoblastic Leukaemia with Two CNS Prophylaxis Regimens". En Acute Leukemias, 483–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_85.
Texto completoReizenstein, Peter. "The Use of Biological Response Modifiers in Acute Myeloid Leukaemia". En New Approaches to the Treatment of Leukemia, 79–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_3.
Texto completoMcCulloch, E. A. "Biological Characteristics of Acute Myeloblastic Leukaemia Contributing to Management Strategy". En New Approaches to the Treatment of Leukemia, 87–116. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75484-5_4.
Texto completoDavis, C. L., A. Z. S. Rohatiner, J. Amess, J. Lim y T. A. Lister. "Treatment of Recurrent Acute Myelogenous Leukaemia at a Single Centre Over a 10-Year Period". En Acute Leukemias II, 339–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_64.
Texto completoRohatiner, A. Z. S., R. Bassan, R. Battista, J. E. Kingston, J. Amess, M. Carter, A. M. Oza et al. "High-Dose Cytosine Arabinoside in the Treatment of Acute Lymphoblastic Leukaemia". En Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 437–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78350-0_78.
Texto completoBarnett, M. J., J. E. Kingston, A. Miller, A. Z. S. Rohatiner, M. A. Horton, M. F. Greaves, J. S. Malpas y T. A. Lister. "Treatment of Minimal Residual Disease in “Poor Risk” Acute Lymphoblastic Leukaemia with High-Dose Cytosine Arabinoside". En Minimal Residual Disease in Acute Leukemia 1986, 205–10. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4273-8_19.
Texto completoTobler, A. y H. P. Koeffler. "Differentiation inducers and their potential use in the treatment of acute myelogenous leukaemia". En Cancer Biology and Medicine, 163–81. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-009-0385-2_6.
Texto completoActas de conferencias sobre el tema "Acute Leukaemia - Treatment"
Guindo, P. Nieto, H. Mateo Carrasco, FD Fernandez Gines y E. Molina Cuadrado. "CP-137 Economic analysis of azacitidine versus decitabine for the treatment of acute myeloid leukaemia". En 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.136.
Texto completoMegías-Vericat, JE, P. Montesinos, MJ Herrero, V. Bosó, F. Moscardó, L. Rojas, D. Martínez-Cuadrón, SF Aliño, MA Sanz y JL Poveda. "PKP-003 Influence of cytarabine metabolic pathway polymorphisms in effectiveness of acute myeloid leukaemia induction treatment". En 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.431.
Texto completoSoliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke y Alaa Elhaddad. "122 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children". En EBM Live. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ebm-2022-ebmlive.37.
Texto completoSoliman, Ranin, Carl Heneghan, Nancy Bolous, Iman Sidhom, Sonia Ahmed, Nia Roberts, Jason Oke y Alaa Elhaddad. "173 Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukaemia in children". En Preventing Overdiagnosis Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/bmjebm-2022-podabstracts.94.
Texto completoAgraz-Doblas, A., C. Bueno, P. Schneider, C. Revilla, T. Moreno, P. Ballerini, M. Bardini, RW Stam, P. Menéndez y I. Varela. "PO-315 The mutational and transcriptome landscape of infant B-cell acute lymphoblastic leukaemia: the INTERFANT treatment protocol experience". En Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.345.
Texto completoLopez-Montero, E., A. Mosquera-Torre, M. Touris-Lores, B. Sanchez-Iglesias, B. Bernardez-Ferran y MJ Lamas-Diaz. "PS-086 Adding low dose allopurinol as hepatoprotector to the maintenance treatment with mercaptopurine in children with acute lymphoblastic leukaemia". En 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.592.
Texto completoGrey, HET y A. Davidson. "G555(P) Does the type of steroid used in the treatment of acute lymphoblastic leukaemia in childhood influence adult weight?" En Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.538.
Texto completoValencia, JC del Río, MRuiz de Villegas Garcia Pelayo, RTamayo Bermejo y I. Muñoz Castillo. "4CPS-105 Blinatumomab for the treatment of the relapse b-precursor acute lymphoblastic leukaemia in a paediatric patient: a case report". En Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.196.
Texto completoHuynh, T., D. Vidovic, C. Dean, K. Lee, I. Weaver y P. Marcato. "PO-372 Investigating the epigenetic changes underlying combination treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide". En Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.400.
Texto completoDel Río Valencia, JC, C. Ortega De La Cruz, T. Chinchilla Alarcón y I. Muñoz Castillo. "4CPS-113 Inotuzumab–ozogamizin for the treatment of relapse B precursor acute lymphoblastic leukaemia in an adult patient: a case report". En 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.214.
Texto completo